BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37416781)

  • 21. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
    Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
    J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
    Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
    Park JA; Wang L; Cheung NV
    J Hematol Oncol; 2021 Sep; 14(1):142. PubMed ID: 34496935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.
    Hix LM; Shi YH; Brutkiewicz RR; Stein PL; Wang CR; Zhang M
    PLoS One; 2011; 6(6):e20702. PubMed ID: 21695190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity.
    Myers DR; Abram CL; Wildes D; Belwafa A; Welsh AMN; Schulze CJ; Choy TJ; Nguyen T; Omaque N; Hu Y; Singh M; Hansen R; Goldsmith MA; Quintana E; Smith JAM; Lowell CA
    Front Immunol; 2020; 11():576310. PubMed ID: 33133093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
    Prasad M; Zorea J; Jagadeeshan S; Shnerb AB; Mathukkada S; Bouaoud J; Michon L; Novoplansky O; Badarni M; Cohen L; Yegodayev KM; Tzadok S; Rotblat B; Brezina L; Mock A; Karabajakian A; Fayette J; Cohen I; Cooks T; Allon I; Dimitstein O; Joshua B; Kong D; Voronov E; Scaltriti M; Carmi Y; Conde-Lopez C; Hess J; Kurth I; Morris LGT; Saintigny P; Elkabets M
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-31 induces antitumor immunity in breast carcinoma.
    Kan T; Feldman E; Timaner M; Raviv Z; Shen-Orr S; Aronheim A; Shaked Y
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
    Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
    Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 36. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
    Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
    Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
    Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
    J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems.
    Yokota Y; Inoue H; Matsumura Y; Nabeta H; Narusawa M; Watanabe A; Sakamoto C; Hijikata Y; Iga-Murahashi M; Takayama K; Sasaki F; Nakanishi Y; Yokomizo T; Tani K
    Blood; 2012 Oct; 120(17):3444-54. PubMed ID: 22936657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.
    Chen L; He Z; Qin L; Li Q; Shi X; Zhao S; Chen L; Zhong N; Chen X
    PLoS One; 2011; 6(9):e24407. PubMed ID: 21931708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.